Lipoprotein patterns and cholesteryl-ester transfer activity (CETA)were examined in a patient with familial hyperalphalipoproteinemia (FHALP). The proband was a 41-year-old Japanese male. He was found to have hypercholesterolemia, with a serum total cholesterol level of 382 mg/dl and a HDL-cholesterol level of 177 mg/dl. HDLshowed a high cholesterol/Apo AI ratio. His father, all of his siblings and one of his children showed high HDL-cholesterol levels (91, 100, 70, 108, 75 and 98 mg/dl, respectively). These data suggest that all members of his family were heterozygotes. He had neither cutaneous or tendinous xanthomasnor any clinical signs of atherosclerosis. The proband appears to have only one-tenth of the normal level of CETA. However, the level of lipid-transfer protein I (LTP-I) activity was near normal. Thus, this patient is most likely to have an exaggerated level of LTP-I inhibitor(s). Effects of probucol on serum lipoprotein and apolipoprotein levels were studied in our patient. Treatment with 250 mg of probucol twice daily reduced total serum cholesterol, low density lipoprotein (LDL) and HDL-cholresterol levels by 33.32 and 33%, respectively. Apo AI, B and E levels decreased by 22, 16 and 35% respecitvely. HDL-cholesterol/Apo AI ratio decreased from 0.9 to 0.76. CETAshowed no significant changes. However, cholesterol ester mass transfer increased from 10.8 to 14.9% after treatment with probucol. These results suggest that probucol appears to be a useful drug for FHALP.
FHALP is transmitted
as an autosomal dominant trait associated with longevity 1"2^.
Recently, five homozygous familial hyperalphalipoproteinemia were reported in Japan. inhibitor(s) may be responsible for FHALP.
DESCRIPTION OF CASE
The patient is a 41-year-old Japanese male who is working as a plumber. He was found to have atherosclerosis.
In his family, cardiovascular disease has never been known to be a cause of death, as judged from questioning surviving relatives.
METHODS
Total cholesterol, triglyceride and phospholipid concentrations in serum after an overnight fast were determined by enzymatic methods using commercital kits (Kyowa Medex Co., Tokyo, Japan) and apo AI, All, B, CII, CIII and apo E were measured by radial immunodiffusion using plates obtained from Daiichi Kagaku Co., Tokyo,
Japan5\
Serum or plasma lipoproteins were separated at preparative ultracentrifugation6) at densities showed high HDL-cholesterol levels (91, 100, 70, 108, 75 and 98 mg/dl, respectively) .
The ratios of HDL-cholesterol to total cholesterol and HDLcholesterol to apo AI were increased in YS, and the ratios in seven first degree relatives were between the levels of YS and normal subjects ( Table  1 , Fig. 1 ). Cholesterol content was extremely high in the HDL2 fraction (133 mg/dl), while it was almost normal in the HDL3fraction. Triglyceride content in the HDL2 fraction from the patient was normal. The HDL2 fraction also had a very high concentration of phospholipid.
Normal and FHALPsera were analyzed by agarose gel column chromatography. The elution patterns Neither of the patient's peaks shifted to the left of those of the control. Isoelectric focusing patterns of apo AI in this patient were studied and were shown to be normal by the method ofWarnick et al.9>.
The patient's LCAT activity and LCAT Serum apo Apo AI levels fell by 22%, from 231 to 185 mg/dl, apo B levels fell by 15%, from 146 to 123 mg/dl and apo E levels fell by 35%, from 5.4
to 3.5 mg/dl (Table 3 ). The elution patterns of serum lipoproteins in this patient were not changed after treatment with probucol (Fig. 2) . CETA showed no significant changes (data not shown). However, cholesterol ester mass transfer increased from 10.8 to 14.7% after treatment with probucol. No adverse effects were observed. DISCUSSION HDL-cholesterol levels in FHALP reported in Japan were extremely high ranging between 160 to 304 mg/dl (4.13 to 7.86 mmol/1) ( Table 4) . Our patient had a HDL-cholesterol of 177 mg/dl, which suggested that he was homozygous for FHALP. His father, all of his siblings and one of his children had high levels of HDL-cholesterol (70-108 mg/dl). These data suggest the possibility that these memberswere heterozygous carriers of FHALP. Apo B levels in all of reported cases in Japan were lower than normal, but our case had a FHALPpresumably accounted for the increase in Probucol lowers the levels of both low-and high density Iipoproteins16\ The mechanisms whereby probucol reduces plasma LDLand HDLhave not yet been elucidated. However, the reduction in plasma HDL levels has been associated with a decreased synthesis of apo Al in man17\ In this study, CETA showed no significant changes.
However, cholesterol ester mass transfer increased from 10.8 to 14.7% after treatment with probucol. These results suggest that probucol appears to be a useful drug for FHALP.
